[News Space=Reporter seungwon lee] As part of its shareholder-friendly policy to enhance shareholder value, KOSPI-listed Yuhan Corporation is acquiring its own stocks worth 2 billion won.

This treasury stock acquisition will be conducted through an on-market purchase in the KOSPI market, and the number of common shares to be acquired is 471,142, and the acquisition amount is 2 billion won. Yuhan Corporation currently holds approximately 850,000 common shares of treasury stock, and upon completion of this treasury stock acquisition, it will hold 7.8% of the total issued common shares as treasury stock.

YuYu Pharma has paid cash dividends for 29 consecutive years since 1994, and this year, it paid a final cash dividend of 100 won for common stock and 120 won for preferred stock, with a total dividend of approximately 2 billion won. In addition, it has continuously implemented shareholder-friendly policies every year, such as purchasing 1 billion won worth of treasury stocks in 2020, a 100% capital increase without payment in 2021, purchasing 2 billion won worth of treasury stocks in 2022, and burning 200,000 treasury stocks in 2023.

Yuhan Corporation CEO Park No-yong said, “We will continue to strive to increase the value of shareholders, including individual investors, who have trusted and invested in Yuhan Corporation’s corporate value and growth potential through shareholder-friendly policies.”

Meanwhile, Yuhan Corporation succeeded in turning around its performance and increasing its profitability by recording consolidated sales of KRW 133.1 billion, operating profit of KRW 11.6 billion, and net profit of KRW 10.2 billion in 2024. It also selected the pet industry as a new growth engine and invested in U.S. startups such as animal drug development companies.